These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12235257)

  • 1. Inhibition of epidermal growth factor receptor-mediated signaling by "Combi-triazene" BJ2000, a new probe for Combi-Targeting postulates.
    Brahimi F; Matheson SL; Dudouit F; McNamee JP; Tari AM; Jean-Claude BJ
    J Pharmacol Exp Ther; 2002 Oct; 303(1):238-46. PubMed ID: 12235257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combi-targeting concept: chemical dissection of the dual targeting properties of a series of "combi-triazenes".
    Rachid Z; Brahimi F; Katsoulas A; Teoh N; Jean-Claude BJ
    J Med Chem; 2003 Sep; 46(20):4313-21. PubMed ID: 13678409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential responses of EGFR-/AGT-expressing cells to the "combi-triazene" SMA41.
    Matheson SL; McNamee JP; Jean-Claude BJ
    Cancer Chemother Pharmacol; 2003 Jan; 51(1):11-20. PubMed ID: 12497201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of action of a novel "combi-triazene" engineered to possess a polar functional group on the alkylating moiety: evidence for enhancement of potency.
    Brahimi F; Rachid Z; McNamee JP; Alaoui-Jamali MA; Tari AM; Jean-Claude BJ
    Biochem Pharmacol; 2005 Aug; 70(4):511-9. PubMed ID: 15982640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combi-targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo.
    Matheson SL; McNamee JP; Wang T; Alaoui-Jamali MA; Tari AM; Jean-Claude BJ
    J Pharmacol Exp Ther; 2004 Dec; 311(3):1163-70. PubMed ID: 15358812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combi-targeting concept: in vitro and in vivo fragmentation of a stable combi-nitrosourea engineered to interact with the epidermal growth factor receptor while remaining DNA reactive.
    Qiu Q; Domarkas J; Banerjee R; Merayo N; Brahimi F; McNamee JP; Gibbs BF; Jean-Claude BJ
    Clin Cancer Res; 2007 Jan; 13(1):331-40. PubMed ID: 17200372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combi-targeting concept: a novel 3,3-disubstituted nitrosourea with EGFR tyrosine kinase inhibitory properties.
    Qiu Q; Dudouit F; Matheson SL; Brahimi F; Banerjee R; McNamee JP; Jean-Claude BJ
    Cancer Chemother Pharmacol; 2003 Jan; 51(1):1-10. PubMed ID: 12497200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type II combi-molecules: design and binary targeting properties of the novel triazolinium-containing molecules JDD36 and JDE05.
    Qiu Q; Domarkas J; Banerjee R; Katsoulas A; McNamee JP; Jean-Claude BJ
    Anticancer Drugs; 2007 Feb; 18(2):171-7. PubMed ID: 17159603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of the cytotoxic potential of the mixed EGFR and DNA-targeting 'combi-molecule' ZRBA1 against human solid tumour cells by a bis-quinazoline-based drug design approach.
    Al-Safadi S; Domarkas J; Han Y; Brahimi F; Jean-Claude BJ
    Anticancer Drugs; 2012 Jun; 23(5):483-93. PubMed ID: 22421369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumor targeting strategy.
    Matheson SL; McNamee J; Jean-Claude BJ
    J Pharmacol Exp Ther; 2001 Mar; 296(3):832-40. PubMed ID: 11181914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR).
    Domarkas J; Dudouit F; Williams C; Qiyu Q; Banerjee R; Brahimi F; Jean-Claude BJ
    J Med Chem; 2006 Jun; 49(12):3544-52. PubMed ID: 16759097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple mechanisms of action of ZR2002 in human breast cancer cells: a novel combi-molecule designed to block signaling mediated by the ERB family of oncogenes and to damage genomic DNA.
    Brahimi F; Rachid Z; Qiu Q; McNamee JP; Li YJ; Tari AM; Jean-Claude BJ
    Int J Cancer; 2004 Nov; 112(3):484-91. PubMed ID: 15382076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and studies on three-compartment flavone-containing combi-molecules designed to target EGFR, DNA, and MEK.
    Larroque-Lombard AL; Todorova M; Qiyu Q; Jean-Claude B
    Chem Biol Drug Des; 2011 May; 77(5):309-18. PubMed ID: 21294849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.
    Showalter HD; Sercel AD; Leja BM; Wolfangel CD; Ambroso LA; Elliott WL; Fry DW; Kraker AJ; Howard CT; Lu GH; Moore CW; Nelson JM; Roberts BJ; Vincent PW; Denny WA; Thompson AM
    J Med Chem; 1997 Feb; 40(4):413-26. PubMed ID: 9046331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: discovery of an unusual structure-activity relationship.
    Rachid Z; Brahimi F; Qiu Q; Williams C; Hartley JM; Hartley JA; Jean-Claude BJ
    J Med Chem; 2007 May; 50(11):2605-8. PubMed ID: 17472358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combi-targeting concept: mechanism of action of the pleiotropic combi-molecule RB24 and discovery of a novel cell signaling-based combination principle.
    Banerjee R; Huang Y; Qiu Q; McNamee JP; Belinsky G; Jean-Claude BJ
    Cell Signal; 2011 Apr; 23(4):630-40. PubMed ID: 21138763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combi-targetinG concept: intracellular fragmentation of the binary epidermal growth factor (EGFR)/DNA targeting "combi-triazene" SMA41.
    Matheson SL; Brahimi F; Jean-Claude BJ
    Biochem Pharmacol; 2004 Mar; 67(6):1131-8. PubMed ID: 15006549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-epidermal growth factor receptor monoclonal antibodies affecting signal transduction.
    Reins HA; Steinhilber G; Freiberg B; Anderer FA
    J Cell Biochem; 1993 Feb; 51(2):236-48. PubMed ID: 8382707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
    Zhou Y; Li S; Hu YP; Wang J; Hauser J; Conway AN; Vinci MA; Humphrey L; Zborowska E; Willson JK; Brattain MG
    Cancer Res; 2006 Jan; 66(1):404-11. PubMed ID: 16397255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.